Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

46.340
+1.9204.32%
Volume:4.43M
Turnover:204.22M
Market Cap:307.56B
PE:33.52
High:46.840
Open:45.200
Low:44.960
Close:44.420
52wk High:94.869
52wk Low:43.020
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:1.59
T/O Rate:1.72%
Dividend:0.23
Dividend Rate:0.51%
EPS(LYR):1.382
ROE:12.46%
ROA:7.02%
PB:4.07
PE(LYR):33.52
PS:8.38

Loading ...

Hengrui Pharma gains NMPA approval for camrelizumab-famitinib as first-line treatment in recurrent/metastatic cervical cancer

Bulletin Express
·
Jul 23

AH Share Premium and Deviation Data for July 22nd

Stock News
·
Jul 22

Movement Alert|Hengrui Pharma Falls 3.22% in Regular Trading, Trading at HK$55.6

Market Focus
·
Jul 21

AH Share Premium and Deviation Data for July 20th

Stock News
·
Jul 20

Movement Alert|Hengrui Pharma Rises 3.36% in Regular Trading, Pharmaceutical Sector Rebounds as Buyback Program Advances

Market Focus
·
Jul 20

Hengrui Pharmaceuticals Completes Share Buyback Totaling 13.75 Million A-Shares

Stock News
·
Jul 19

Hengrui Pharma Executes Share Buyback, Spending Over 15 Million Yuan on July 17

Stock News
·
Jul 17

Hengrui Pharma Gets China Clinical Trial Nod for Osteoarthritis Injection; Shares Fall 4%

MT Newswires Live
·
Jul 17

Movement Alert|Hengrui Medicine Falls 3.19% in Regular Trading, Pharmaceutical Sector Broadly Weak Despite Pipeline Progress

Market Focus
·
Jul 17

AH Share Premium and Deviation Analysis for July 16th

Stock News
·
Jul 16

Hengrui Pharmaceuticals Gets Nod for Atopic Dermatitis Drug Testing

MT Newswires Live
·
Jul 16

Hengrui Pharma's HRS-8797 Tablet Receives Clinical Trial Approval Notification

Stock News
·
Jul 15

AH Share Premium and Deviation Data as of July 15th

Stock News
·
Jul 15

Movement Alert|Hengrui Medicine Rises 3.17% in Regular Trading, Pipeline Catalysts and Sector Recovery Drive Rebound

Market Focus
·
Jul 15

Mingyu Pharma, Led by Hengrui Veteran, Files for Hong Kong IPO Amid Fierce Market Competition

Deep News
·
Jul 15

Movement Alert|Hengrui Medicine Falls 3.05% in Regular Trading, FDA Issues Third Complete Response Letter for PD-1 Combination Therapy

Market Focus
·
Jul 14

Hengrui Pharmaceuticals Gets China Nod For Lupus, Arthritis Drug Trials

MT Newswires Live
·
Jul 14

Hengrui Pharma's HRS-7058 Capsule Designated as Breakthrough Therapy

Stock News
·
Jul 13

Hengrui Pharma's FXI Antibody SHR-2004 Unveils Pivotal Phase III Data at ISTH 2026 LBA Session

Deep News
·
Jul 13

AH Share Premium and Deviation Rankings as of July 13th Close

Stock News
·
Jul 13